Sandesh Seth
CIK: 0001566175
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Actinium Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Sep 2, 2026ATNM
Actinium Pharmaceuticals, Inc.
Award(A)Direct753.6K shares- - Sep 2, 2026ATNM
Actinium Pharmaceuticals, Inc.
Award(A)Direct1M shares- - Aug 18, 2025ATNM
Actinium Pharmaceuticals, Inc.
Tax Payment(F)Direct120.9K shares at avg. $1.71$207K - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
16.7K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
25K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
33.3K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
50K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
139.1K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
310.2K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
827.4K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
984.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | Award(A) | 753,600 | - | $0 | Direct |
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | Award(A) | 1,027,274 | - | $0 | Direct |
| Aug 18, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Tax Payment(F) | 120,900 | $1.71 | $206,739 | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 16,666 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 33,333 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 139,062 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 310,182 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 827,366 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 984,367 | - | - | Direct |
1-11 of 11 transactions
About SETH SANDESH
SETH SANDESH (SEC CIK 0001566175) files insider reports with the SEC as Chief Executive Officer of Actinium Pharmaceuticals, Inc. (ATNM).
Signal8 holds 3 ownership filings by SETH SANDESH, all Form 4s, filed between Apr 2, 2025 and Sep 4, 2026. Those filings report 11 transactions, from Mar 31, 2025 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SETH SANDESH's filings is in NEW YORK, NY.
Recent filings by SETH SANDESH
Other insiders filing for Actinium Pharmaceuticals, Inc. (ATNM)
- David Matthew T, Chief Financial Officer
- Kamal Adeela, Chief Scientific Officer
- Heeger Steffen Wilhem, Chief Medical Officer
- Shetty Ajit, Director
- Nicholson, C. David, Director
- Almenoff June Sherie, Director